NCT05795595View on ClinicalTrials.gov

A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

March 13, 2023

Primary Completion Date

April 30, 2030

Study Completion Date

May 31, 2030

Conditions
Clear Cell Renal Cell CarcinomaCervical CarcinomaEsophageal CarcinomaPancreatic AdenocarcinomaMalignant Pleural Mesothelioma
Interventions
BIOLOGICAL

CTX131

CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)

Trial Locations (7)

27710

RECRUITING

Research Site 4, Durham

37203

RECRUITING

Research Site 1, Nashville

60637

RECRUITING

Research Site 7, Chicago

63110

RECRUITING

Research Site 2, St Louis

77030

RECRUITING

Research Site 5, Houston

91010

RECRUITING

Research Site 3, Duarte

02215

RECRUITING

Research Site 6, Boston

Sponsors
All Listed Sponsors
lead

CRISPR Therapeutics AG

INDUSTRY

NCT05795595 - A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors | Biotech Hunter | Biotech Hunter